Zydus Lifesciences Limited (ZYDUSLIFE) has announced a significant step towards expanding its international footprint. On 13 October 2026, Zydus Sunshine Lifesciences (Pvt) Ltd, the joint venture between Zydus Lifesciences Limited and Sunshine Healthcare, signed an agreement with the Board of Investment of Sri Lanka to establish a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka. This strategic move is expected to commence commercial operations by 2028, subject to project timelines and regulatory approvals.

Phased Investment of Over USD 20 Million

The project involves a phased investment of over USD 20 million. The facility will be developed on a site of nearly four acres. In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market. This investment supports Zydus’ commitment to expanding access to quality medicines and strengthens the company’s international presence.

Strengthening Medicine Supply Chain Resilience

Local manufacturing is anticipated to enhance medicine supply chain resilience and support the availability of essential medicines in Sri Lanka. As a result, Zydus Lifesciences Limited (ZYDUSLIFE) is poised to make a substantial impact on the pharmaceutical landscape in Sri Lanka and beyond. This agreement marks a pivotal moment for the company as it continues to grow and innovate in the global pharmaceutical sector.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock gains 0.5% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Zydus Lifesciences Limited (ZYDUSLIFE) announced the conclusion of a USFDA inspection at its manufacturing plant located in Moraiya, Ahmedabad. The inspection, conducted from October 5th to October 13th, 2026, concluded with five observations noted by the USFDA. The company will closely collaborate with the USFDA to address these observations promptly. This announcement is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Inspection Details

The USFDA conducted a thorough inspection of the company’s manufacturing facility. The primary objective was to ensure compliance with Good Manufacturing Practices (GMP) and other regulatory requirements. The inspection team identified five observations that need to be addressed by the company.

Company’s Response

Zydus Lifesciences Limited has assured that it will work closely with the USFDA to resolve the observations expeditiously. The company’s management emphasized their commitment to maintaining high standards of quality and compliance in all its operations. The observations will be addressed in a timely manner to ensure continued adherence to regulatory requirements.

Forward-Looking Statement

As a result of this inspection, Zydus Lifesciences Limited remains dedicated to improving its manufacturing processes and ensuring the highest quality standards for its products. The company looks forward to maintaining a strong relationship with the USFDA and other regulatory bodies.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.69 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock gains 1.2% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Zydus Lifesciences Limited (ZYDUSLIFE) has announced that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda®. This marks the first publicly announced acceptance by the USFDA of an application for a Keytruda® biosimilar. The BLA was submitted in the third quarter of 2026.

Significant Milestone

The acceptance of the application is a significant step toward expanding access to affordable pembrolizumab therapy in the U.S. and Canada. The regulatory dossier for FYB206 has also been submitted to Health Canada. This development is expected to improve patient access and outcomes in oncology treatment.

Development Pathway

FYB206 was developed without a comparative Phase III efficacy trial, following a development pathway agreed upon with the USFDA in early 2025. Zydus holds exclusive commercialization rights for the United States and Canada and brings extensive commercial experience in the North American market for this product.

Future Outlook

Under the Biosimilar User Fee Amendments (BsUFA), the USFDA aims to complete its review within twelve months of submission. A decision could be expected in the third quarter of 2027. With this milestone, Zydus and Formycon aim to make this important cancer therapy accessible to more patients.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 75% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.